Comparing Two Treatments for Colorectal Cancer That Spread to the Lungs
Compares surgery and radiotherapy for a few colorectal cancer spots in the lungs.
Plain-language title generated from the registry record
Registry title: Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy
Key facts
- Where
- Amsterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with 1 to 3 lung metastases from colorectal cancer who can have either keyhole surgery or focused radiotherapy (SABR).
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- 1 to 3 lung metastases from colorectal cancer, confirmed on imaging and by tissue testing; the original colorectal cancer was fully treated; earlier liver metastases were fully treated; ECOG performance status 0 - 2.
- Earlier treatment
- The original colorectal cancer must have been fully treated. Any earlier liver metastases must have been fully treated with the aim of removing all disease.
Main reasons for not taking part
- Metastases outside the liver or lungs, now or before
- Another cancer now, or in the past 5 years (except certain low-risk cancers)
- Cancer spread to lymph nodes at the lung root or in the chest centre
- Poor heart and lung function tests
- Cannot treat all colorectal metastases, or surgery would need removal of two lung lobes or a whole lung
Read by machine on 12 November 2026.
Where in Netherlands
- Amsterdam University Medical Center (AUMC)Amsterdam, NetherlandsContact: Martijn van Dorp, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Amsterdam UMC, location VUmc
- Trial code
- NCT05808790
- Record updated
- 11 April 2023
- Original description
COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastasesRead full original descriptionShow less
Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy: a Phase III Multicenter Randomized Controlled Trial
COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastases
Inclusion: Age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG)-Performance status 0 - 2; Willing to provide informed consent; Patients with 1 to 3 lung metastases from colorectal cancer eligible for both a minimally invasive surgical resection and SABR, as assessed by the multidisciplinary tumor board (MDT); Radically treated primary colorectal cancer; Patient is able and willing to complete the quality-of-life questionnaires; Previous liver metastases are radically treated with curative intent; Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
Exclusion: Previous or present metastases outside liver or lungs; Surgical resection by means of a bilobectomy or pneumonectomy; Concurrent malignant cancer, or history of other malignant cancers within the past 5 years (excluding prespecified low-risk cancers); Hilar or mediastinal lymph node metastases; Poor cardiopulmonary function test; Inability to treat all colorectal metastases.